Euclid Phoenix Lens Design Trial 2
Launched by EUCLID SYSTEMS CORPORATION · Apr 26, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Euclid Phoenix Lens Design Trial 2 is a research study designed to compare the comfort and wetness of two types of special contact lenses, called orthokeratology lenses, in children aged 6 to 35 who need vision correction for nearsightedness (myopia). The trial will involve 50 participants who currently wear Euclid Emerald lenses and will check how well these lenses fit and feel, especially looking at a new coating that might improve their experience. Additionally, the study will monitor changes in eye length, which can be important for understanding how myopia progresses in children.
To participate, children must have parental consent if they are under legal age, need to currently wear specific myopia-correcting lenses, and should have good vision without serious eye problems. They will need to attend follow-up visits during the study. It’s important to note that those with certain eye conditions, recent eye surgeries, or specific health issues may not be eligible. This trial is not yet recruiting participants, but it aims to help improve the comfort and effectiveness of lenses for young patients with myopia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be of legal age or, if under legal age have written consent of their parent or guardian to participate.
- • Sign written Informed Consent (and the California Bill of Rights, if applicable).
- • Ages 6-35 (inclusive) and able to understand and assent to participation
- • Current wearers of Euclid Emerald (Oprifocon A) Orthokeratology lenses, which at initiation of fitting, had
- • Need of optical correction for myopia, from -1.00 to -5.00 Diopters (D).
- • Refractive astigmatism of less than -1.50 D.
- • Have a minimum Best Spectacle Corrected Visual Acuity (BSCVA) of 20/40 or better in each eye.
- • Have acceptable or optimal fit with study lenses (once fitting has been completed) and be willing to wear these lenses as directed for the duration of the study.
- * On examination, have ocular findings considered to be within normal limits, including:
- • No evidence of active infection involving the conjunctiva, lids or adnexa.
- • No evidence of structural abnormalities of the lid, conjunctiva or adnexal tissue considered significant by the investigator to include minimum levels (Grade 2 or less) of tarsal-conjunctival abnormalities
- • Clear corneas with no evidence of edema, staining, opacities, corneal neovascularization greater than a trace amount (i.e. All vessels extending less than 1.5 mm from the limbus); all as observed on slit lamp examination.
- • No iritis.
- • No herpes keratitis (recurrent or otherwise) or other active ocular disease that would contraindicate lens wear or lessen attainability of VA sought in this study (20/40 or better).
- • No evidence of dry eye or meibomian gland dysfunction
- • Normal binocularity (no amblyopia or strabismus, and no anisometropia of greater than 2.00D)
- • Be willing and able to follow instructions and attend the schedule of follow-up visits.
- Exclusion Criteria:
- • Does not meet the any of the above inclusion criteria
- • Not able or willing to provide informed consent and assent
- • Requires concurrent ocular medication
- • Eye injury or surgery within twelve weeks immediately prior to enrollment
- • Pre-existing ocular condition that would preclude contact lens fitting
- • Currently enrolled in an ophthalmic clinical trial
- • Pregnant or lactating or expect to become pregnant during the trial
- • Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
- • Allergy or sensitivity to any product used in this trial
- • Any systemic disease including autoimmune disease, immunocompromising diseases, connective tissue disease, clinically significant atopic diseases, insulin dependent diabetes, use of medications including corticosteroids and antimetabolites that may affect the eye or be exaggerated by contact lenses.
- • Strabismus/amblyopia
- • Habitual uncorrected anisometropia ≥ 2.00D
- • Subjects who have undergone corneal refractive surgery
- • Subjects with severe corneal irregularity contraindicating lens wear
- • Inability to wear contact lenses, or an unacceptable contact lens fit
- • Poor or unacceptable fit with any study lens
- • Employees, staff or family members of personnel at the site
About Euclid Systems Corporation
Euclid Systems Corporation is a leading clinical trial sponsor specializing in innovative solutions for the advancement of healthcare research. With a commitment to enhancing patient outcomes, the company leverages cutting-edge technology and data analytics to streamline clinical trial processes and improve efficiencies. Euclid Systems collaborates with a diverse range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers, to facilitate the successful development of new therapies and medical devices. Their expertise encompasses all phases of clinical trials, ensuring rigorous adherence to regulatory standards while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Memphis, Tennessee, United States
Kirkland, Washington, United States
Edina, Minnesota, United States
Sartell, Minnesota, United States
North Brunswick, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported